Population Pharmacokinetic and Pharmacodynamic Model‐Based Comparability Assessment of a Recombinant Human Epoetin Alfa and the Biosimilar HX575

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of clinical pharmacology

• Publication date

  2012-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/0091270011421911PMID 22162538PMCID PMC3483448
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• R: A language and environment for statistical computing.

  2014cited by this paper
• Interpretation of transit compartments pharmacodynamic models as lifespan based indirect response models

  2011cited by this paper
• Selection between Michaelis–Menten and target-mediated drug disposition pharmacokinetic models

  2010cited by this paper
• Pharmacodynamics-Mediated Drug Disposition (PDMDD) and Precursor Pool Lifespan Model for Single Dose of Romiplostim in Healthy Subjects

  2010cited by this paper
• Exposure‐Response Modeling of Darbepoetin Alfa in Anemic Patients With Chronic Kidney Disease Not Receiving Dialysis

  2010cited by this paper
• Population Modeling of Filgrastim PK‐PD in Healthy Adults Following Intravenous and Subcutaneous Administrations

  2010cited by this paper
• Evidence of Receptor-Mediated Elimination of Erythropoietin by Analysis of Erythropoietin Receptor mRNA Expression in Bone Marrow and Erythropoietin Clearance During Anemia

  2010influential reference
• Investigation of the effects of altered receptor binding activity on the clearance of erythropoiesis-stimulating proteins: Nonerythropoietin receptor-mediated pathways may play a major role.

  2009cited by this paper
• Bioequivalence Tests Based on Individual Estimates Using Non-compartmental or Model-Based Analyses: Evaluation of Estimates of Sample Means and Type I Error for Different Designs

  2009cited by this paper
• Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple intravenous administrations: an open-label randomised controlled trial

  2009cited by this paper
• Pharmacokinetic and Pharmacodynamic Modeling of Pegylated Thrombopoietin Mimetic Peptide (PEG‐TPOm) After Single Intravenous Dose Administration in Healthy Subjects

  2009cited by this paper
• Pharmacokinetics and Pharmacodynamics of the Erythropoietin Mimetibody™ Construct CNTO 528 in Healthy Subjects

  2009cited by this paper
• Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update.

  2008cited by this paper
• Population Pharmacokinetics and Pharmacodynamics of Peptidic Erythropoiesis Receptor Agonist (ERA) in Healthy Volunteers

  2008cited by this paper
• Bioequivalence of HX575 (Recombinant Human Epoetin Alfa) and a Comparator Epoetin Alfa after Multiple Subcutaneous Administrations

  2008influential reference
• Modeling time variant distributions of cellular lifespans: increases in circulating reticulocyte lifespans following double phlebotomies in sheep

  2008cited by this paper
• Pharmacodynamic Analysis of Recombinant Human Erythropoietin Effect on Reticulocyte Production Rate and Age Distribution in Healthy Subjects

  2008cited by this paper
• Basic pharmacodynamic models for agents that alter the lifespan distribution of natural cells

  2008cited by this paper
• Erythropoietins: a common mechanism of action.

  2008cited by this paper
• Design and Analysis of Bioavailability and Bioequivalence Studies, The Third Edition

  2008cited by this paper
• Population Pharmacokinetics Meta-Analysis of Recombinant Human Erythropoietin in Healthy Subjects

  2007cited by this paper
• Change in Erythropoietin Pharmacokinetics Following Hematopoietic Transplantation

  2007influential reference
• Diagnosing Model Diagnostics

  2007cited by this paper
• Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO)

  2007cited by this paper
• Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid malignancies undergoing multicycle chemotherapy

  2006cited by this paper
• Cellular Trafficking and Degradation of Erythropoietin and Novel Erythropoiesis Stimulating Protein (NESP)*

  2006influential reference
• Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia.

  2006cited by this paper
• Efficacy prospective study of different frequencies of Epo administration by i.v. and s.c. routes in renal replacement therapy patients.

  2006cited by this paper
• The Utility of the Population Approach Applied to Bioequivalence in Patients: Comparison of 2 Formulations of Cyclosporine

  2005cited by this paper
• Population Cell Life Span Models for Effects of Drugs Following Indirect Mechanisms of Action

  2005cited by this paper
• Erythropoietin: the story of hypoxia and a finely regulated hematopoietic hormone.

  2005cited by this paper
• The Visual Predictive Check Superiority to Standard Diagnostic (Rorschach) Plots

  2005cited by this paper
• Quasi-Equilibrium Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition

  2005cited by this paper
• Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects.

  2005cited by this paper
• Unaltered Etanercept Pharmacokinetics With Concurrent Methotrexate in Patients With Rheumatoid Arthritis

  2004cited by this paper
• Efficacy of once-weekly epoetin alfa.

  2004cited by this paper
• Oxygen sensing by HIF hydroxylases

  2004cited by this paper
• Control of rHuEPO biological activity: the role of carbohydrate.

  2004cited by this paper
• Pharmacokinetic and Pharmacodynamic Modeling of Recombinant Human Erythropoietin After Single and Multiple Doses in Healthy Volunteers

  2004cited by this paper
• Apoptotic mechanisms in the control of erythropoiesis

  2004cited by this paper
• Statistical Issues in a Modeling Approach to Assessing Bioequivalence or PK Similarity with Presence of Sparsely Sampled Subjects

  2004cited by this paper
• Design and Analysis of Bioavailability and Bioequivalence Studies

  2003cited by this paper
• Diversity of mechanism-based pharmacodynamic models.

  2003cited by this paper
• Optimizing the use of erythropoietic agents-- pharmacokinetic and pharmacodynamic considerations.

  2002cited by this paper
• New insights into erythropoiesis

  2002influential reference
• General Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition

  2001cited by this paper
• Cessation of intensive treatment with recombinant human erythropoietin is followed by secondary anemia.

  2001cited by this paper
• Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: evidence for bone marrow as a major erythropoietin elimination pathway.

  2001cited by this paper
• Signal transduction in the erythropoietin receptor system.

  1999cited by this paper
• Characterization of the highly variable bioavailability of tiludronate in normal volunteers using population pharmacokinetic methodologies

  1999cited by this paper
• Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients.

  1999cited by this paper
• Basic Pharmacodynamic Models for Agents That Alter Production of Natural Cells

  1999cited by this paper
• Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena.

  1998cited by this paper
• Pharmacokinetics of erythropoietin in genetically anemic mice.

  1998cited by this paper
• A Comparison of the Standard Approach and the NONMEM Approach in the Estimation of Bioavailability in Man

  1997cited by this paper
• Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats.

  1997influential reference
• Bioequivalence: Individual and Population Compartmental Modeling Compared to the Noncompartmental Approach

  1996influential reference
• rh‐Erythropoietin stimulates immature reticulocyte release in man

  1994influential reference
• Survival or death of individual proerythroblasts results from differing erythropoietin sensitivities: a mechanism for controlled rates of erythrocyte production.

  1993influential reference
• The International Standard for Recombinant DNA-derived Erythropoietin: collaborative study of four recombinant DNA-derived erythropoietins and two highly purified human urinary erythropoietins.

  1992cited by this paper
• Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case for subcutaneous administration.

  1992cited by this paper
• Erythropoietin receptor characteristics on primary human erythroid cells.

  1991cited by this paper
• Dynamics of erythropoietin receptor expression on erythropoietin-responsive murine cell lines.

  1990cited by this paper
• Application of the NONMEM method to evaluation of the bioavailability of drug products.

  1990cited by this paper
• Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells.

  1990influential reference
• Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers.

  1990influential reference
• Pharmacokinetics of recombinant human erythropoietin after SC administration and in long-term IV treatment in patients on maintenance hemodialysis.

  1989cited by this paper
• Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial.

  1989cited by this paper
• Binding of iodinated erythropoietin to rat bone marrow cells under normal and anemic conditions.

  1989cited by this paper
• Quantitation of specific binding of erythropoietin to human erythroid colony‐forming cells

  1988cited by this paper
• Expression of high affinity receptors for erythropoietin on human bone marrow cells and on the human erythroleukemic cell line, HEL.

  1988cited by this paper
• The erythropoietin receptor of rat erythroid progenitor lens. Characterization and affinity cross-linkage.

  1987cited by this paper
• Cloning and expression of the human erythropoietin gene.

  1985cited by this paper
• Operational models of pharmacological agonism

  1983cited by this paper
• Purification of human erythropoietin.

  1977cited by this paper
• Purification of human erythropoietin.

  1972cited by this paper

• Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling for Iron-Regulated Hematopoietic Stem and Progenitor Cells' Commitment toward Erythroid and Megakaryocytic Lineages.

  2025cites this paper
• Erythropoietin hyporesponsiveness in non‐alcoholic fatty liver disease

  2024cites this paper
• Early erythroferrone levels can predict the long‐term haemoglobin responses to erythropoiesis‐stimulating agents

  2024cites this paper
• Scaling Pharmacodynamics from Rats to Humans to Support Erythropoietin and Romiplostim Combination Therapy to Treat Erythropoietin-Resistant Anemia

  2023cites this paper
• Thrombopoietin treats erythropoietin resistance by correcting EPO-induced progenitorcell depletion.

  2023cites this paper
• Novel Combination of Erythropoietin and Romiplostim to Treat Chemotherapy-Induced Anemia and Thrombocytopenia via Pharmacodynamic Interaction on Hematopoietic Stem and Progenitor Cells

  2023cites this paper
• Importance of Target‐Mediated Drug Disposition (TMDD) of Small‐Molecule Compounds and Its Impact on Drug Development—Example of the Class Effect of HSD‐1 Inhibitors

  2022cites this paper
• A Novel Combination Therapy of Erythropoietin and Thrombopoietin to Treat Erythropoietin-Resistance anemia

  2022cites this paper
• Efficacy and safety of MIL60 compared with bevacizumab in advanced or recurrent non-squamous non-small cell lung cancer: a phase 3 randomized, double-blind study

  2021cites this paper
• Facile imprinted polymer for label-free highly selective potentiometric sensing of proteins: case of recombinant human erythropoietin

  2021cites this paper
• Application of Pharmacokinetic-Pharmacodynamic Modeling in Drug Delivery: Development and Challenges

  2020cites this paper
• Dose Correction for a Michaelis–Menten Approximation of a Target-Mediated Drug Disposition Model with a Multiple Intravenous Dosing Regimens

  2020cites this paper
• Sensitivity of Pegfilgrastim Pharmacokinetic and Pharmacodynamic Parameters to Product Differences in Similarity Studies

  2019cites this paper
• Hematopoietic Growth Factors

  2019cites this paper
• Pharmacometric models in the development of biological medicinal products

  2019cites this paper
• Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin®) in patients with advanced non-squamous non-small cell lung cancer

  2019cites this paper
• Concept of Pharmacologic Target‐Mediated Drug Disposition in Large‐Molecule and Small‐Molecule Compounds

  2019influential citation
• Semi‐mechanistic Pharmacokinetic/Pharmacodynamic model of three pegylated rHuEPO and ior®EPOCIM in New Zealand rabbits

  2018cites this paper
• A model of hematopoietic bone marrow apoptosis during growth factor deprivation in combination with a cytokine

  2018cites this paper
• General Pharmacokinetic Features of Small‐Molecule Compounds Exhibiting Target‐Mediated Drug Disposition (TMDD): A Simulation‐Based Study

  2018cites this paper
• Application of Pharmacometric Analysis in the Design of Clinical Pharmacology Studies for Biosimilar Development

  2018cites this paper
• Comparable pharmacokinetics and pharmacodynamics of two epoetin alfa formulations Eporon® and Eprex® following a single subcutaneous administration in healthy male volunteers

  2017cites this paper
• Small‐Molecule Compounds Exhibiting Target‐Mediated Drug Disposition (TMDD): A Minireview

  2017cites this paper
• Pharmacodynamic and Pharmacokinetic Equivalences of Epoetin Hospira and Epogen(®) After Multiple Subcutaneous Doses to Healthy Male Subjects.

  2016cites this paper
• A cell-level model of pharmacodynamics-mediated drug disposition

  2016cites this paper
• Utilisation et développement de techniques pharmacocinétiques avancées afin d’améliorer le développement de molécules pharmaceutiques

  2015cites this paper
• Small‐molecule compounds exhibiting target‐mediated drug disposition — A case example of ABT‐384

  2015cites this paper
• Assessment of hemoglobin responsiveness to epoetin alfa in patients on hemodialysis using a population pharmacokinetic pharmacodynamic model

  2015cites this paper
• A Tutorial on Target-Mediated Drug Disposition (TMDD) Models

  2015cites this paper
• A model of hematopoietic stem cell proliferation under the influence of a chemotherapeutic agent in combination with a hematopoietic inducing agent

  2014cites this paper
• Hematopoietic Growth Factors: Focus on Erythropoiesis-Stimulating Agents

  2013cites this paper
• Multiple‐dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA‐IgG1), a novel erythropoietic agent, in healthy postmenopausal women

  2013influential citation
• Romiplostim dose-response in patients with myelodysplastic syndromes.

  2013cites this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Erythropoiesis-Stimulating Agents

  2013cites this paper
• Quantitative assessment of minimal effective concentration of erythropoiesis-stimulating agents

  2013cites this paper
• The use of pharmacometrics to optimize biosimilar development.

  2013cites this paper